An open-label, multicenter, phase 1b/2 study of navtemadlin (KRT-232) in patients with relapsed/refractory acute myeloid leukemia secondary to myeloproliferative neoplasms

Previous early phase clinical trials with the use of navtemadlin (KRT-232), an MDM2 inhibitor, in patients with relapsed/refractory acute myeloid leukemia and intermediate-high risk myelofibrosis have shown clinical activity with disease-modifying effects. Patients with acute myeloid leukemia secondary to a myeloproliferative neoplasm have limited treatment options and poor median overall survival of <6 months. This open-label, multicenter phase 1b/2 KRT-232-104 study is ongoing and actively enrolling patients.